Minerva Neurosciences, Inc. (NERV) Financials

NERV Assets vs Liabilities
DateAssetsLiabilities
Dec. 31, 2023 56.9 billion 85.4 billion
Sept. 30, 2023 63.1 million 83.2 million
June 30, 2023 67.1 million 79.6 million
March 31, 2023 51.6 million 78.2 million

NERV Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2023 -6.0 million 611064
Sept. 30, 2023 -6.9 million 371943
June 30, 2023 -3.9 million 608915
March 31, 2023 -115407 376459

NERV Net Income

No data available :(

NERV Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2023 40.9 billion - -
Sept. 30, 2023 46.9 million - -
June 30, 2023 51.8 million - -
March 31, 2023 36.0 million - -

NERV Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Dec. 31, 2023 6.5 million
Sept. 30, 2023 7.6 million
June 30, 2023 5.5 million
March 31, 2023 5.3 million

NERV Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2023 - 4.7 million 2.5 million -7746
Sept. 30, 2023 - 3.4 million 2.6 million -
June 30, 2023 - 1.9 million 2.6 million -
March 31, 2023 - 2.7 million 2.7 million -

NERV Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2023 - 7746
Sept. 30, 2023 - 7745
June 30, 2023 - 7746
March 31, 2023 - 7745

NERV

Price: $4.47

52 week price:
1.57
12.46

Earnings Per Share: -1.85 USD

P/E Ratio: -3.25

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 48300

Ebitda: -11.1 million

Market Capitalization: 34.7 million

Links: